Biogen have just announced they will be going ahead and filing Aducanumab (their treatment for Alzheimer’s Disease).
Shares are +40% as a result.
This is extremely odd considering just in March the studies were discontinued due to futility (i.e. they didn’t show an effect).
The company is saying new analysis of a larger dataset has led to, in communication with the FDA, the filing decision (NB. approval is uncertain still).
There is a huge unmet need [100% of drugs have failed, the disease affects 5.8m people in America (50m worldwide) and costs $290bn per year in direct and care costs] so perhaps there was pressure for a win.
